Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis.

Name: Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis.
Author: Kloppenburg, Margreet

Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. — المؤلف: Kloppenburg, Margreet — Annals of the rheumatic diseases 20191202

المؤلف: Kloppenburg, Margreet
النشر: Annals of the rheumatic diseases 20191202
الوصف: 413-420 p.
الموضوعات: Adult؛ Aged؛ Aged, 80 and over؛ Arthralgia؛ C-Reactive Protein؛ Double-Blind Method؛ Female؛ Hand Joints